Ask AI
ProCE Banner Activity

New and Emerging Targeted Therapies for Patients With DLBCL

Podcast

The management of patients with DLBCL is rapidly changing with several targeted agents across different drug classes on the near horizon. Experts discuss the potential utility of surovatamig, a novel bispecific antibody targeting CD19 and CD3 in overcoming resistance to CD20-targeted therapies, and the potential roles of golcadomide, a first-in-class oral CELMoD, and tafasitamab plus lenalidomide and R-CHOP in untreated DLBCL. They also discuss ongoing trials of other bispecific antibodies and acalabrutinib, a BTK inhibitor, in DLBCL.

Listen to this podcast with 2 experts from Europe and the United States discussing the unmet clinical needs in DLBCL, the expanding role of approved targeted therapies, challenges with access to these new therapies in different regions, important ongoing clinical trials of new and novel agents in DLBCL that are poised to change practice, and key presentations and results in DLBCL reported at the recent 2026 European Hematology Association Congress in Sweden.

Released: August 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel targeted therapies in DLBCL

  • Evaluate the potential clinical application of emerging evidence for novel targeted therapies in DLBCL

  • Recommend the optimal targeted treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence

  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel targeted therapies

Financial Disclosures

Primary Author

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Genmab, GSK, Incyte, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, Novartis; researcher (paid to institution): AbbVie, Daiichi Sankyo, Genentech, Genmab, Ipsen, Janssen.

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.